Hepalink: Enoxaparin Sodium Injection Receives New Manufacturer Approval from EMA
Hepalink announced that the company recently received an approval notice from the European Medicines Agency (EMA) regarding the addition of a manufacturer of enoxaparin sodium injection. The drug involved in the approval is enoxaparin sodium injection, with the trade name Inhixa, and the dosage form is injection, with specifications including 20mg/0.2ml, 40mg/0.4ml, 60mg/0.6ml, 80mg/0.8ml, 100mg/1ml, 120mg/0.8ml, 150mg/1ml. The new manufacturer is Shenzhen Hepalink Pharmaceutical Group Co., Ltd., and the production site is located at No. 1 Rongtian Road, Kengzi Street, Pingshan District, Shenzhen, China, with an approval number of EMA/VR/262,500. This approval will provide the company with more sufficient production capacity guarantee for further promoting the internationalization strategy of preparations and effectively improve the company's market competitiveness.